New Delhi, May 23 -- GLP-1 inhibitors, a class of diabetes and weight-loss drugs already credited with reducing the risk of heart attacks and strokes, may also slow the spread of certain cancers, according to a large real-world study presented at an American oncology conference in Chicago on Friday. According to a press release by the American Society of Clinical Oncology (ASCO), researchers at Cleveland Clinic's Taussig Cancer Institute examined health records of over 10,000 patients with early-to-mid-stage cancer who had begun taking GLP-1 receptor agonists - drugs that mimic a gut hormone called glucagon-like peptide-1, which regulates blood sugar and appetite - after cancer diagnosis. They compared this group against patients taking DPP...